Talquetamab

AL Amyloidosis

St. Olavs Hospitalmonoclonal_antibodyActive

D

30/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 15/ 100
Competitive Position: 81/ 100

Competitive context

20 Active assets in the AL Amyloidosis cohort.

Asset / Sponsor	Phase	Rating
DEXAMETHASONE St. Olavs Hospital	Phase 3	BB
Cyclophosphamide Alexion Pharmaceuticals, Inc.	Phase 3	B
Florbetaben University of Zurich	Phase 3	B
Selinexor Washington University School of Medicine	Phase 2	B
Anselamimab Alexion Pharmaceuticals, Inc.	Phase 3	B

View all 22 →

Same molecule, other indications

Talquetamab is also rated in:

plasma cell myelomaDormant

BB

Indicative ·

66 / 100

Waldenstrom macroglobulinemiaDormant

BB

Indicative ·

65 / 100

hematopoietic and lymphoid system neoplasmDormant

B

Indicative ·

60 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.